How Long Does It Take to See Results with GLP-1 Agonists like Mounjaro or Wegovy?

In recent years, medications like Wegovy (Semaglutide) and Mounjaro (Tirzepatide) have taken the world by storm, revolutionising the management of Type 2 diabetes and obesity. Their profound impact on blood sugar control and weight loss has generated headlines and offered new hope to millions. But what if this was just the beginning? What if the next generation of metabolic medicine could deliver even more powerful results?

Enter Retatrutide, an investigational medicine that is rapidly becoming one of the most talked-about drugs in development.

Nicknamed the "Triple G" drug, Retatrutide is currently undergoing extensive Phase 3 clinical trials and is not yet available to the public.

Its unique power lies in its ability to target not one, not two, but three key metabolic hormone receptors, a triple-action mechanism that promises to push the boundaries of what's possible in diabetes and weight management.

This article will delve into the ground-breaking science to discover how Retatrutide could revolutionise diabetes and weight loss management with its triple-agonist action.

How Retatrutide Works: The 'Triple G' Advantage

The excitement surrounding Retatrutide stems from its sophisticated and unprecedented mechanism of action. While older drugs target a single hormone pathway, Retatrutide is a triple receptor agonist, engaging with three distinct hormones that play a crucial role in regulating our metabolism, appetite, and blood sugar. This multi-pronged attack is what sets it apart and gives it a potential clinical edge. 

To understand its power, we need to break down each component of its "Triple G" action:

• GLP-1 (Glucagon-like peptide-1) Receptor Agonism: This is the same mechanism used by drugs like Ozempic and Wegovy. Activating the GLP-1 receptor tells the brain you are full, significantly reducing appetite. It also slows down the rate at which your stomach empties, prolonging the feeling of satiety after a meal. For individuals with Type 2 diabetes, it stimulates the pancreas to release insulin in response to high blood sugar levels.
• GIP (Glucose-dependent insulinotropic polypeptide) Receptor Agonism: This is the second target, which Retatrutide shares with the dual-agonist drug Mounjaro. GIP also enhances the body's insulin release in response to glucose, working synergistically with GLP-1 to improve blood sugar control. Furthermore, research suggests GIP may play a role in how the body processes and stores fat.
• Glucagon Receptor Agonism: This is Retatrutide's unique and game-changing feature. While it might seem counterintuitive to activate the receptor for glucagon, a hormone that raises blood sugar, the effect in this context is profoundly different. Activating the glucagon receptor in combination with GLP-1 and GIP appears to increase energy expenditure. In simple terms, it helps the body burn more calories and fat, even at rest. This action specifically targets the liver, reducing fat accumulation and improving overall metabolic health.

This triple-action mechanism results in a powerful synergy. The GLP-1 and GIP components work together to control blood sugar and suppress appetite, while the glucagon component accelerates fat burning and energy use. For a person with Type 2 diabetes, this combination is revolutionary. It not only addresses high blood sugar (hyperglycaemia) but also tackles one of the primary drivers of the condition: excess body weight, particularly visceral fat. The strong link between weight loss and improved diabetes outcomes is well-established, with bodies like the American Diabetes Association (ADA) highlighting that significant weight reduction can even lead to remission in some cases.

Clinical Breakthroughs in Diabetes Treatment

The theoretical promise of Retatrutide's triple-action mechanism has been powerfully validated by its clinical trial results. The data from the Phase 2 trial, published in The Lancet, has sent waves of excitement through the medical community. The study evaluated the drug's effects on individuals with Type 2 diabetes over 36 weeks, revealing unprecedented efficacy in both blood sugar control and weight loss.

Focus on HbA1c (Glycosylated Haemoglobin) and Glucose Control

A key measure for diabetes management is HbA1c, which reflects average blood glucose levels over the preceding two to three months. According to NICE guidelines in the UK, a target HbA1c for adults with Type 2 diabetes is typically 48 mmol/mol (6.5%) or lower.

In the Phase 2 trial, participants receiving the highest doses of Retatrutide saw their HbA1c levels fall by a staggering average of 2.02% (22.1 mmol/mol). This reduction is significantly greater than that seen with many existing diabetes medications. To put this into perspective, a large number of participants achieved levels that are considered non-diabetic:

• 92% of participants on the 8mg dose achieved an HbA1c of 6.5% or less.
• An incredible 78% of participants on the 12mg dose reached an HbA1c below 5.7%, which is the threshold for normal glucose levels in individuals without diabetes.

These results suggest that Retatrutide has the potential not just to manage Type 2 diabetes, but to normalise blood sugar

The Weight Loss Factor

While glucose control was impressive, the weight-loss results were truly groundbreaking.

Obesity is a major risk factor and complicating factor for Type 2 diabetes, and achieving substantial weight loss is critical for improving insulin sensitivity and overall health.

The trial participants on the highest dose of Retatrutide lost an average of 16.9% of their body weight (around 17.5 kg or 38.6 lbs) in just 36 weeks. A separate Phase 2 trial focusing on obesity, published in The New England Journal of Medicine, showed even more profound results over a longer period, with participants losing up to 24.2% of their body weight at 48 weeks.

This level of weight loss, achieved without intensive surgical intervention, was previously unimaginable for a pharmaceutical drug. Crucially, a substudy using advanced imaging techniques revealed that this weight loss was primarily due to a reduction in fat mass, not muscle. 

Participants lost up to 26.1% of their total fat mass while largely preserving lean muscle tissue, which is vital for maintaining metabolic health and physical strength. This targeted fat reduction directly contributes to improved insulin sensitivity and can significantly ease the metabolic burden of Type 2 diabetes.

Retatrutide vs. Mounjaro (Tirzepatide) and Ozempic (Semaglutide)

The Edge: Why Triple Action Matters

The research data strongly suggest that adding glucagon receptor agonism provides a significant clinical advantage. While Mounjaro's dual action demonstrated the benefit of targeting more than one pathway, Retatrutide's third mechanism appears to unlock a new level of efficacy. The glucagon action's ability to increase energy expenditure and burn fat on top of the appetite suppression and insulin regulation from GLP-1 and GIP creates a comprehensive metabolic treatment that tackles the problem from three different angles. This is why experts believe Retatrutide could offer superior and more durable results for both diabetes control and weight reduction.

Crucial Warning: Availability and Safety

While the clinical trial results for Retatrutide are incredibly promising, it is absolutely vital for the public to understand its current status. 

Current Investigational Status

Retatrutide is an investigational drug and is NOT approved for public use anywhere in the world yet ( 12 December 2025), including the United Kingdom.

If you see advertisements for Retatrutide or its compounded form on social media like TikTok or Instagram, you should not purchase it, as this substance is currently an investigational drug, has not been approved by the MHRA or other regulatory bodies for prescription or sale, and is only legally available to participants in clinical trials, which are not expected to conclude until 2026 at the earliest; consequently, any website or seller offering it is doing so illegally, and buying unregulated, non-pharmacy grade compounds carries serious health risks, including potential contamination, incorrect dosages, and severe adverse effects.

The Dangers of the Unregulated Trade

The extraordinary public appetite for these groundbreaking new metabolic drugs has, regrettably, given rise to a perilous unregulated trade for unapproved substances. Unscrupulous sellers are frequently peddling these products online, often marketing them dishonestly as "research peptides" in an attempt to sidestep crucial regulations. It is absolutely vital that the public understands the serious risks associated with buying these illicit products:

• Uncertain Dosage and Purity: Products from the unregulated supply chain are subject to no quality control whatsoever. The active substance you receive could be underdosed, overdosed, or, indeed, contain an entirely different active ingredient to what was advertised.
• Absence of Sterility: Injectable medicines must be manufactured in strictly sterile environments. Illicit products are routinely concocted under unsanitary conditions, presenting a significant risk of bacterial contamination and subsequent serious infection.
• Dangerous Contaminants: Vials sourced through these illegal channels may be contaminated with heavy metals, unidentified chemical by-products, or other deeply harmful substances.
• Risk of Severe Side Effects: Taking such a potent, unapproved drug without proper medical supervision could trigger life-threatening adverse reactions, including severe hypoglycaemia (dangerously low blood sugar), pancreatitis, heart complications, and acute allergic reactions.

Regulatory bodies are actively cracking down on this illegal trade. The MHRA recently announced a raid on an illegal manufacturing facility, seizing thousands of doses of unapproved products. This highlights the very real and present danger of the unregulated market.

Conclusion

Retatrutide represents a potential paradigm shift in the treatment of Type 2 diabetes and obesity. Its unique triple-action mechanism has delivered unprecedented results in clinical trials, offering the possibility of not just managing these chronic conditions, but of normalising key metabolic markers to a degree previously thought impossible with medication alone.

The significant reductions in HbA1c and body weight point to a future where medicine moves beyond simple glucose control and towards a more comprehensive and holistic approach to metabolic health. However, excitement must be tempered with patience and caution.

The global medical community now awaits the results of the large-scale Phase 3 trials to confirm these promising findings and, most importantly, to establish a long-term safety profile. Retatrutide is a beacon of hope and a testament to the incredible pace of medical innovation. While it is not a solution for today, it provides a tantalising glimpse into the future of metabolic medicine, a future that looks brighter and more hopeful than ever before.

Don't Wait for Tomorrow

You do not have to wait for Retatrutide to be approved.

You can start transforming your life and health today with currently approved, effective treatments like Wegovy or Mounjaro (where clinically appropriate).

Looking for effective and weight management solutions? Discover our evidence-based weight loss programme at SheMed, designed for lasting results and delivered with clinical excellence.

Key Takeaways from SheMed

1. It's a "Triple Threat" Drug: Retatrutide uniquely targets three metabolic hormone receptors (GLP-1, GIP, and glucagon), making it potentially more powerful for blood sugar and weight loss than current single or dual-action drugs.
2. Promising But Preliminary: Clinical trial results show unprecedented efficacy (e.g., ~24% weight loss), but it remains an investigational drug. It is NOT approved for use by any regulatory authority worldwide.
3. Zero Legal Availability: It will not be available for prescription until at least 2026-2027. Any product being sold now is illegal, counterfeit, and dangerous.
4. Severe Safety Warning: Obtaining it outside of clinical trials poses extreme risks, including contamination, incorrect dosing, infection, and severe side effects. Only use MHRA/TGA/FDA-approved medications prescribed by your doctor.

Frequently Asked Questions (FAQs)

1. What is Retatrutide?
   A "Triple G" investigational drug that targets three hormone receptors for potentially superior blood sugar and weight control. It is not approved anywhere yet.
2. How does Retatrutide compare to Wegovy or Mounjaro?
   It is a triple-hormone agonist (GLP-1, GIP, glucagon), while Wegovy is single and Mounjaro is dual, which may lead to stronger effects. However, it is not yet approved, unlike the others.

References

1. Jastreboff, A. M., et al. (2023). Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. The New England Journal of Medicine, 389(6), 514-526. DOI: 10.1056/NEJMoa2301972.
2. Rosenstock, J., et al. (2023). Efficacy and safety of a novel triple hormone receptor agonist retatrutide in people with type 2 diabetes: A randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial in the USA. The Lancet. DOI: 10.1016/S0140-6736(23)01727-4.
3. American Diabetes Association (2022). Weight Loss is Key to Remission of Type 2 Diabetes. Press Release. Available at: https://diabetes.org/newsroom/press-releases/2022/weight-loss-key-remission-type-2-diabetes.
4. National Institute for Health and Care Excellence (NICE). (2022). Type 2 diabetes in adults: management. NG28. Available at: https://www.nice.org.uk/guidance/ng28.
5. Medicines and Healthcare products Regulatory Agency (MHRA). (2023). MHRA and partners shut down illegal manufacturing of weight loss products. Press Release. Available at: https://www.gov.uk/government/news/mhra-and-partners-shut-down-illegal-manufacturing-of-weight-loss-products.

‍

For millions of people, living with Type 2 Diabetes (T2D) and Peripheral Artery Disease (PAD) presents a daily challenge. These conditions, often intertwined, can cast a long shadow over quality of life, with one of the most debilitating symptoms being a sharp, cramping pain in the legs while walking. This pain, known as intermittent claudication, can turn a simple walk to the shops into a gruelling ordeal, severely limiting mobility and independence.

According to Diabetes UK, over 4.3 million people are now living with a diagnosis of diabetes in the UK, while the British Heart Foundation estimates that PAD affects a significant portion of the population, often going undiagnosed.

Semaglutide, a medication well-known under brand names like Wegovy for its powerful effects on blood sugar control and weight management, has emerged as a subject of intense interest. Researchers hypothesised that its benefits might extend beyond metabolic health, potentially improving blood flow and reducing inflammation in the legs of those with PAD. This led to a crucial clinical investigation: the STRIDE (Semaglutide Treatment on Walking Distance in Peripheral Artery Disease) trial.

This article provides a comprehensive analysis of the STRIDE trial and explores the mechanism of Semaglutide, and breaks down the trial's methodology and results.

Understanding PAD and Type 2 Diabetes

Before exploring the trial itself, it's essential to understand the two conditions at its core. Peripheral Artery Disease and Type 2 Diabetes are distinct diagnoses, but their relationship is deeply interconnected, creating a complex clinical picture for many patients.

What Is Peripheral Artery Disease (PAD)

Peripheral Artery Disease is a common circulatory problem in which narrowed arteries reduce blood flow to your limbs, most commonly the legs.

According to the NHS, this narrowing is caused by atherosclerosis, a process where fatty deposits, or plaques, build up on the artery walls. When the arteries supplying blood to your legs become partially or fully blocked, the leg muscles don't receive enough oxygen-rich blood to meet the demands of physical activity.

The classic symptom of this oxygen deficit is intermittent claudication. This is characterised by:

• Pain on exertion: A painful aching, cramping, or feeling of fatigue in the muscles of the calves, thighs, or buttocks that appears during walking or climbing stairs.
• Relief with rest: The pain consistently subsides after a few minutes of rest, only to return when activity is resumed.

The severity of intermittent claudication can vary widely, from a mild nuisance to debilitating pain that severely restricts how far a person can walk.

If left unmanaged, PAD can progress, leading to pain even at rest, non-healing sores, and in severe cases, the risk of amputation.

The Link Between Type 2 Diabetes and PAD

The connection between T2D and PAD is not coincidental; it is a dangerous synergy. Individuals with Type 2 Diabetes are at a significantly higher risk of developing PAD, and when they do, it is often more severe and progresses more rapidly.

This heightened risk is driven by several factors linked to diabetes:

• Accelerated Atherosclerosis: High blood glucose levels can damage the inner lining of the arteries (the endothelium), making them more susceptible to the buildup of fatty plaques.
• Inflammation: T2D is associated with chronic low-grade inflammation throughout the body, which is a key driver of the atherosclerotic process.
• Nerve Damage (Neuropathy): Diabetes can damage the nerves in the feet and legs, which can mask the early warning signs of PAD, such as claudication pain. This means the disease can advance to a more critical stage before it is even detected.

Research published in journals like Diabetes Care has consistently shown that people with diabetes are two to four times more likely to develop PAD than those without. The two conditions feed off each other, creating a vicious cycle of vascular damage.

Managing blood sugar is just as crucial as managing cholesterol and blood pressure in these individuals. Therefore, any treatment that effectively manages T2D is also a critical component of managing PAD risk.

Semaglutide: Mechanism, Usage, and Potential Benefits

Semaglutide or Wegovy has become a popular in diabetes care and, more recently, in weight management. Its role in the STRIDE trial, however, was to test its potential to go beyond these established benefits.

What is Semaglutide?

Semaglutide is a medication known as a GLP-1 receptor agonist. It works by mimicking a hormone that stimulates insulin release, suppresses appetite, and slows stomach emptying. It is widely used for managing Type 2 Diabetes. Wegovy, a higher-dose version, is also approved for weight management. Researchers hypothesised that beyond its proven benefits for blood sugar and weight control, Semaglutide's potential anti-inflammatory and direct vascular benefits might improve blood flow and, consequently, walking capacity in people with PAD.

Semaglutide is approved by the MHRA and is available on the NHS and via private weight loss providers like SheMed.

Beyond Blood Sugar Control: The Potential Benefits for PAD

The hypothesis for the STRIDE trial was rooted in growing evidence that the benefits of GLP-1 receptor agonists like Semaglutide are not limited to glucose control. Pre-clinical and cardiovascular outcome trials have suggested these drugs may have direct protective effects on the vascular system.

Researchers believed Semaglutide could potentially help with PAD through:

• Anti-inflammatory Effects: As mentioned, inflammation is a key driver of atherosclerosis. Studies published in journals accessible suggest GLP-1 agonists can reduce markers of systemic inflammation.
• Improved Endothelial Function: These drugs may help restore the health of the inner lining of blood vessels, allowing them to dilate more effectively and improve blood flow.
• Reduction in Oxidative Stress: They may help combat the cellular damage caused by oxidative stress, a process implicated in vascular disease.

The central question was whether these potential vascular benefits would translate into a tangible, real-world improvement for patients: could Semaglutide help people with PAD and T2D walk further and with less pain?

The STRIDE Trial: Design and Methodology

The STRIDE Trial (Semaglutide Treatment on Walking Capacity in Patients With Peripheral Artery Disease and Type 2 Diabetes) was designed as a rigorous Randomised Controlled Trial (RCT), the gold standard for clinical evidence. The study enrolled a specific cohort of patients: those suffering from both symptomatic PAD and Type 2 Diabetes. Participants were randomly assigned to receive either Semaglutide or a placebo. 

STRIDE Trial Results: The Impact on Walking Capacity

The STRIDE trial results delivered a clear and positive message. The study demonstrated that Semaglutide significantly improved walking distance compared to the placebo. Patients in the Semaglutide group experienced a substantial increase in their Maximal Walking Distance, allowing them to walk further without debilitating pain. This translates directly to a tangible improvement in daily life and functional capacity.

Furthermore, the benefits extended beyond mobility. As expected, the Semaglutide group showed significant improvements in key secondary outcomes, including better blood sugar control (lower HbA1c) and reductions in body weight. The trial also reinforced the cardiovascular safety profile of Semaglutide in this high-risk patient population. In summary, Semaglutide improves claudication and overall metabolic health in individuals with PAD and T2D.

Primary and Secondary Endpoints from Trial

In any clinical trial, the "endpoints" are the key outcomes measured to determine if the treatment works.

• Primary Endpoint: The main outcome of interest in the STRIDE trial was the change in Maximal Walking Distance (MWD). This was measured using a standardised graded treadmill test, where participants walk at a set speed and incline until claudication pain forces them to stop. The total distance walked is the MWD.
• Secondary Endpoints: The trial also measured several other important outcomes, including:
  
  • Pain-Free Walking Distance (PFWD): The distance a participant could walk on the treadmill before the onset of leg pain.
  • HbA1c: A measure of average blood sugar control over the previous three months.
  • Body Weight: Changes in weight from the beginning to the end of the trial.
  • Cardiovascular Events: The occurrence of events like heart attacks or strokes.
  • Quality of Life: Measured using validated patient questionnaires.

Adverse Events and Tolerability

The safety profile of Semaglutide observed in the STRIDE trial was consistent with its known side effects. The most commonly reported adverse events were gastrointestinal in nature, including:

• Nausea
• Vomiting
• Diarrhoea

These side effects were more common in the Semaglutide group than in the placebo group and are a well-documented aspect of initiating treatment with GLP-1 receptor agonists. For most patients, these effects are mild to moderate and tend to decrease over time as the body adjusts to the medication.

Conclusion

The STRIDE Trial provides strong evidence that Semaglutide like Wegovy can significantly improve walking capacity in people living with both Peripheral Artery Disease and Type 2 Diabetes. Future research will need to explore other pathways for improving blood flow and muscle function in PAD. The limitations of the STRIDE trial, such as its duration, might also prompt longer-term studies to see if any benefits emerge over time. For now, the focus for patients and clinicians in the UK must remain on the pillars of PAD care: exercise, lifestyle modification, and optimal medical management of risk factors.

Key Takeaways 

1. Significant Improvement in Walking Ability: The trial demonstrated that Semaglutide provides a direct and meaningful benefit for mobility. Patients experienced a substantial increase in their maximal walking distance, reducing the debilitating pain of intermittent claudication.
2. Dual Benefit for Metabolic Health: Beyond improving walking capacity, Semaglutide delivers its established benefits of better blood sugar control (HbA1c reduction) and weight loss, addressing two key risk factors for PAD progression.
3. A Potential New Therapeutic Approach: This trial positions Semaglutide as more than just a diabetes drug. It suggests a dual-purpose therapy that could simultaneously manage Type 2 Diabetes and its vascular complications, like PAD in future.
4. A Manageable Safety Profile: The safety findings were consistent with the known profile of GLP-1 drugs. The main side effects were gastrointestinal (e.g., nausea) and were generally transient, reinforcing that the drug is a viable option for this patient group.

Frequently Asked Questions (FAQs)

1. What was the main finding of the STRIDE trial?
The STRIDE trial found that Semaglutide significantly improved walking distance for people with Peripheral Artery Disease (PAD) and Type 2 Diabetes. Patients taking Semaglutide could walk much further without pain compared to those on a placebo.

2. What are the common side effects of Semaglutide?
The most common side effects are gastrointestinal, including nausea, vomiting, diarrhoea, and constipation. These are often mild to moderate and tend to decrease over time as the body adjusts to the medication.

References

1. Diabetes UK. (n.d.). Diabetes prevalence. Retrieved from https://www.diabetes.org.uk/professionals/position-statements-reports/statistics
2. British Heart Foundation. (n.d.). BHF UK Factsheet. Retrieved from https://www.bhf.org.uk/what-we-do/our-research/heart-statistics
3. NHS. (n.d.). Peripheral arterial disease (PAD). Retrieved from https://www.nhs.uk/conditions/peripheral-arterial-disease-pad/
4. Iqbal, Z., et al. (2023). Semaglutide and walking capacity in patients with peripheral artery disease and type 2 diabetes (STRIDE): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet Diabetes & Endocrinology, 11(12), 914-924. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00509-4/abstract 

‍